MA33888B1 - Neutralisation des anticorps du recepteur de la prolactine et utilisation therapeutique associee - Google Patents

Neutralisation des anticorps du recepteur de la prolactine et utilisation therapeutique associee

Info

Publication number
MA33888B1
MA33888B1 MA34951A MA34951A MA33888B1 MA 33888 B1 MA33888 B1 MA 33888B1 MA 34951 A MA34951 A MA 34951A MA 34951 A MA34951 A MA 34951A MA 33888 B1 MA33888 B1 MA 33888B1
Authority
MA
Morocco
Prior art keywords
prolactin
neutralization
benign
therapeutic use
receptor antibodies
Prior art date
Application number
MA34951A
Other languages
Arabic (ar)
English (en)
Inventor
Christoph Freiberg
Axel Harrenga
Simone Greven
Mark Trautwein
Sandra Bruder
Andrea Eicker
Christiane Otto
Siegmund Wolf
Andreas Wilmen
Original Assignee
Bayer Ip Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42091520&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33888(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh filed Critical Bayer Ip Gmbh
Publication of MA33888B1 publication Critical patent/MA33888B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne la neutralisation de l'anticorps de la prolactine - C04, ainsi que ses formes mûres, et des fragments de liaison à un antigène, des compositions pharmaceutiques les contenant et leur utilisation dans le traitement ou la prévention de troubles bénins et d'indications médiées par le récepteur de la prolactine, par exemple l'endométriose, l'adénomyose, la contraception femelle non hormonale, la maladie bénigne du sein et la mastalgie, l'inhibition de la lactation, l'hyperplasie bénigne de la prostate, les fibroïdes, la perte de cheveux hyper et normoprolactinémique, et le co-traitement thérapeutique hormonal combiné pour inhiber la prolifération cellulaire épithéliale mammaire. Les anticorps selon l'invention bloquent la signalisation médiée par le récepteur de la prolactine.
MA34951A 2009-12-10 2010-11-18 Neutralisation des anticorps du recepteur de la prolactine et utilisation therapeutique associee MA33888B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09075546A EP2332995A1 (fr) 2009-12-10 2009-12-10 Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique
PCT/EP2010/067747 WO2011069799A1 (fr) 2009-12-10 2010-11-18 Neutralisation des anticorps du recepteur de la prolactine et utilisation therapeutique associee

Publications (1)

Publication Number Publication Date
MA33888B1 true MA33888B1 (fr) 2013-01-02

Family

ID=42091520

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34951A MA33888B1 (fr) 2009-12-10 2010-11-18 Neutralisation des anticorps du recepteur de la prolactine et utilisation therapeutique associee

Country Status (40)

Country Link
US (6) US9241989B2 (fr)
EP (13) EP2332995A1 (fr)
JP (7) JP2013513364A (fr)
KR (2) KR101765968B1 (fr)
CN (6) CN102858803A (fr)
AP (1) AP2012006343A0 (fr)
AR (6) AR079349A1 (fr)
AU (2) AU2010330161B2 (fr)
BR (2) BR112012015852B8 (fr)
CA (6) CA2783513C (fr)
CL (2) CL2012001540A1 (fr)
CR (2) CR20120310A (fr)
CU (2) CU23973B1 (fr)
CY (2) CY1118209T1 (fr)
DK (2) DK2510002T3 (fr)
DO (2) DOP2012000160A (fr)
EA (2) EA028678B1 (fr)
EC (2) ECSP12011965A (fr)
ES (2) ES2603352T3 (fr)
GT (1) GT201200186A (fr)
HR (2) HRP20170016T1 (fr)
HU (2) HUE031631T2 (fr)
IL (2) IL220151A0 (fr)
IN (2) IN2012DN05082A (fr)
LT (2) LT2510006T (fr)
MA (1) MA33888B1 (fr)
ME (1) ME02577B (fr)
MX (2) MX2012006621A (fr)
NZ (2) NZ600511A (fr)
PE (3) PE20171134A1 (fr)
PH (2) PH12012501131A1 (fr)
PL (2) PL2510002T3 (fr)
PT (2) PT2510006T (fr)
RS (2) RS55277B1 (fr)
SG (2) SG181511A1 (fr)
SI (2) SI2510006T1 (fr)
TN (1) TN2012000294A1 (fr)
TW (5) TW201130506A (fr)
WO (6) WO2011069799A1 (fr)
ZA (2) ZA201204214B (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2332995A1 (fr) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique
HUE047173T2 (hu) 2010-03-01 2020-04-28 Bayer Healthcare Llc Optimalizált monoklonális ellenanyagok szöveti faktor útvonal inhibitor (TFPI) ellen
EP2530089A1 (fr) 2011-06-03 2012-12-05 Bayer Pharma Aktiengesellschaft Anticorps neutralisant Mat3 contre le récepteur de prolactine et son utilisation thérapeutique
MX361875B (es) 2012-03-14 2018-12-18 Regeneron Pharma Moléculas de unión de antígeno multiespecifícas y usos de las mismas.
US8883979B2 (en) * 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
CN105102480B (zh) * 2012-12-24 2019-04-16 艾伯维公司 催乳素受体结合蛋白及其用途
EP2968538A1 (fr) * 2013-03-15 2016-01-20 Bayer HealthCare LLC Formulations d'anticorps anti-récepteurs de prolactine
TWI641620B (zh) 2013-08-21 2018-11-21 再生元醫藥公司 抗－ｐｒｌｒ抗體及其用途
US9545451B2 (en) 2013-08-21 2017-01-17 Regeneron Pharmaceuticals, Inc. Anti-PRLR antibodies and methods for killing PRLR-expressing cells
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
CN117442748A (zh) 2014-10-02 2024-01-26 希望之城公司 多价中间表位、中间表位结合抗体及其用途
BR112017015661A2 (pt) 2015-01-30 2018-03-20 Saitama Medical University anticorpo anti-alk2
MY189159A (en) 2015-07-06 2022-01-29 Regeneron Pharma Multispecific antigen-binding molecules and uses thereof
WO2017190079A1 (fr) 2016-04-28 2017-11-02 Regeneron Pharmaceuticals, Inc. Procédés de production de molécules multispécifiques se liant à l'antigène
WO2018102304A1 (fr) 2016-11-29 2018-06-07 Regeneron Pharmaceuticals, Inc. Méthodes de traitement du cancer du sein positif à prlr
FR3062213B1 (fr) * 2017-01-20 2021-02-26 Endodiag Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose
TW201836647A (zh) 2017-04-06 2018-10-16 美商艾伯維有限公司 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途
US11202776B2 (en) * 2017-05-12 2021-12-21 Takeda Pharmaceutical Company Limited Treatment of gastroparesis with triazaspiro[4.5]decanone
PE20200481A1 (es) 2017-07-10 2020-03-03 Bayer Pharma AG Anticuerpo del receptor de prolactina para la perdida de cabello con patrones masculinos y femeninos
JP7779653B2 (ja) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 治療用タンパク質送達のための方法および組成物
WO2019169330A1 (fr) * 2018-03-02 2019-09-06 Oncolix, Inc. Procédé de traitement de cancers exprimant le récepteur de la prolactine
CN109627340B (zh) * 2018-12-05 2021-02-12 上海交通大学 Cd3和prlr双特异性抗体及其构建与应用
US10467487B1 (en) * 2018-12-11 2019-11-05 Chongqing Jinkang New Energy Automobile Co., Ltd. Fusion-based traffic light recognition for autonomous driving
CN112425568A (zh) * 2020-12-11 2021-03-02 上海市计划生育科学研究所 一种建立具有emt特征的良性前列腺增生bph犬模型的方法
UY39610A (es) 2021-01-20 2022-08-31 Abbvie Inc Conjugados anticuerpo-fármaco anti-egfr
CN114853890B (zh) * 2022-03-16 2023-04-28 沈阳三生制药有限责任公司 一种prlr抗原结合蛋白及其制备方法和应用
CN114634574B (zh) * 2022-04-18 2022-12-20 先进生物(苏州)有限公司 抗B7H6的scFv抗体、其编码基因及其应用
CN120842400A (zh) * 2023-04-24 2025-10-28 深圳真实生物医药科技有限公司 泌乳素受体抗体及其用途
CN117285625B (zh) * 2023-11-24 2024-01-23 南京佰抗生物科技有限公司 抗泌乳素蛋白的单克隆抗体及应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4986615A (en) 1988-10-17 1991-01-22 The Vendo Company Vending apparatus
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
GB9105245D0 (en) * 1991-03-12 1991-04-24 Lynxvale Ltd Binding molecules
EP1291360A1 (fr) 1991-12-13 2003-03-12 Xoma Corporation Procedes et matieres de preparation de domaines variables d'anticorps modifies et leurs utilisations therapeutiques
AU725609C (en) 1995-08-18 2002-01-03 Morphosys Ag Protein/(poly)peptide libraries
WO1998010765A1 (fr) * 1996-09-13 1998-03-19 The Board Of Trustees Of The Leland Stanford Junior University Methode contraceptive non hormonale
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
US6867187B2 (en) * 2000-12-22 2005-03-15 Trustees Of The University Of Pennsylvania Composition and method for modulating somatolactogenic function
EP1325930A1 (fr) * 2002-01-08 2003-07-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Variants de Prolactin de mammifère
CA2509825A1 (fr) * 2002-12-13 2004-07-01 The Ohio State University Antagonistes de la prolactine humaine
GB0305790D0 (en) * 2003-03-13 2003-04-16 Glaxosmithkline Biolog Sa Novel Composition
CA2585977C (fr) * 2004-10-28 2013-07-02 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'endometriose
WO2006089678A2 (fr) * 2005-02-22 2006-08-31 Bioinvent International Ab Peptides et utilisations de ceux-ci
GB0517878D0 (en) * 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
US7422899B2 (en) 2005-10-05 2008-09-09 Biogen Idec Ma Inc. Antibodies to the human prolactin receptor
AR062435A1 (es) * 2006-08-18 2008-11-05 Xoma Technology Ltd Anticuerpo especifico prlr (receptor de prolactina) y sus usos
CN102711773A (zh) 2007-05-30 2012-10-03 奥克兰联合服务有限公司 生长激素和相关激素的抑制剂,和其使用方法
EP2025683A1 (fr) * 2007-08-13 2009-02-18 INSERM (Institut National de la Santé et de la Recherche Medicale) Variantes de prolactine servant comme antagonistes de son récepteur
EP2332995A1 (fr) * 2009-12-10 2011-06-15 Bayer Schering Pharma Aktiengesellschaft Neutralisation d'anticorps récepteurs de prolactine et leur utilisation thérapeutique
WO2011139375A1 (fr) * 2010-05-06 2011-11-10 Ludwig Institute For Cancer Research Ltd Anticorps dirigés contre l'anhydrase carbonique ix et méthodes et utilisations associées
GB201020995D0 (en) * 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof

Also Published As

Publication number Publication date
CN102947338B (zh) 2015-11-25
PE20121360A1 (es) 2012-10-11
EP2510006B1 (fr) 2016-11-09
ECSP12011966A (es) 2012-07-31
EA201200860A1 (ru) 2013-01-30
JP2013513559A (ja) 2013-04-22
WO2011069795A1 (fr) 2011-06-16
PL2510002T3 (pl) 2017-02-28
AR079351A1 (es) 2012-01-18
JP2013513361A (ja) 2013-04-22
US9649374B2 (en) 2017-05-16
BR112012015852B1 (pt) 2020-12-29
WO2011069795A4 (fr) 2011-08-18
AR079352A1 (es) 2012-01-18
CN102884082B (zh) 2015-05-20
CN102858804A (zh) 2013-01-02
JP2013513364A (ja) 2013-04-22
PH12012501131A1 (en) 2017-08-23
AR079350A1 (es) 2012-01-18
NZ600511A (en) 2014-01-31
WO2011069798A1 (fr) 2011-06-16
CA2783513A1 (fr) 2011-06-16
HRP20161401T1 (hr) 2016-12-16
HUE030143T2 (en) 2017-04-28
JP6066474B2 (ja) 2017-01-25
IN2012DN05082A (fr) 2015-10-09
US20120321632A1 (en) 2012-12-20
EP2510006A1 (fr) 2012-10-17
EP2567977A1 (fr) 2013-03-13
CA2783514A1 (fr) 2011-06-16
JP2013513363A (ja) 2013-04-22
HRP20170016T1 (hr) 2017-02-24
IL220151A0 (en) 2012-07-31
US9241989B2 (en) 2016-01-26
CA2783513C (fr) 2018-08-14
TW201130507A (en) 2011-09-16
EA201200851A1 (ru) 2013-01-30
ECSP12011965A (es) 2012-07-31
MX339343B (es) 2016-05-20
KR20120112527A (ko) 2012-10-11
CN102884082A (zh) 2013-01-16
LT2510006T (lt) 2016-12-12
JP2013513362A (ja) 2013-04-22
KR101765968B1 (ko) 2017-08-08
WO2011069794A1 (fr) 2011-06-16
ES2603352T3 (es) 2017-02-27
HUE031631T2 (en) 2017-07-28
AU2010330165B2 (en) 2015-07-16
SI2510002T1 (sl) 2016-12-30
RS55277B1 (sr) 2017-02-28
SG181513A1 (en) 2012-07-30
EA028678B1 (ru) 2017-12-29
TWI487536B (zh) 2015-06-11
EP2510007A1 (fr) 2012-10-17
CY1118407T1 (el) 2017-06-28
NZ600512A (en) 2014-11-28
IL220149A (en) 2017-09-28
AU2010330161B2 (en) 2015-07-09
EP2567979A1 (fr) 2013-03-13
EP2570435A1 (fr) 2013-03-20
CY1118209T1 (el) 2017-06-28
JP6199930B2 (ja) 2017-09-20
CA2783651A1 (fr) 2011-06-16
TW201130506A (en) 2011-09-16
PT2510002T (pt) 2016-11-23
EP2510002A1 (fr) 2012-10-17
DOP2012000159A (es) 2012-09-30
CU23973B1 (es) 2013-12-27
US20130129739A1 (en) 2013-05-23
EA029327B1 (ru) 2018-03-30
GT201200186A (es) 2014-01-06
SI2510006T1 (sl) 2017-02-28
MX2012006621A (es) 2012-10-05
CN102947338A (zh) 2013-02-27
CA2783610A1 (fr) 2011-06-16
DK2510006T3 (en) 2017-01-23
EP2567980A1 (fr) 2013-03-13
AR079348A1 (es) 2012-01-18
CN102741291A (zh) 2012-10-17
EP2510003A1 (fr) 2012-10-17
BR112012015852A2 (pt) 2017-05-23
WO2011069797A1 (fr) 2011-06-16
RS55589B1 (sr) 2017-06-30
MX2012006620A (es) 2012-06-21
CR20120310A (es) 2012-08-01
JP2015180690A (ja) 2015-10-15
HK1180700A1 (en) 2013-10-25
TN2012000294A1 (en) 2013-12-12
EP2332995A1 (fr) 2011-06-15
EP2510004A1 (fr) 2012-10-17
AU2010330161A1 (en) 2012-07-05
BR112012014048B1 (pt) 2021-10-26
EP2567978A1 (fr) 2013-03-13
LT2510002T (lt) 2016-11-25
ME02577B (fr) 2017-06-20
CR20120312A (es) 2012-08-27
AU2010330165A1 (en) 2012-07-19
BR112012015852B8 (pt) 2021-05-25
SG181511A1 (en) 2012-07-30
ZA201204214B (en) 2014-08-27
TW201130505A (en) 2011-09-16
CA2783654A1 (fr) 2011-06-16
EP2570436A1 (fr) 2013-03-20
TWI508744B (zh) 2015-11-21
CL2012001540A1 (es) 2013-01-18
IN2012DN05078A (fr) 2015-10-23
CU20120093A7 (es) 2012-10-15
US20130171147A1 (en) 2013-07-04
EP2510002B1 (fr) 2016-08-24
AP2012006343A0 (en) 2012-06-30
CN102858801A (zh) 2013-01-02
WO2011069796A1 (fr) 2011-06-16
WO2011069799A1 (fr) 2011-06-16
TW201138817A (en) 2011-11-16
PL2510006T3 (pl) 2017-06-30
KR20120112528A (ko) 2012-10-11
BR112012015852A8 (pt) 2017-06-27
JP2013513365A (ja) 2013-04-22
IL220149A0 (en) 2012-07-31
US20120315276A1 (en) 2012-12-13
AR079349A1 (es) 2012-01-18
KR101790366B1 (ko) 2017-10-26
CN102858803A (zh) 2013-01-02
DOP2012000160A (es) 2012-09-30
CA2783610C (fr) 2018-10-30
PE20121561A1 (es) 2012-11-25
CL2012001539A1 (es) 2012-10-12
US20130022606A1 (en) 2013-01-24
PT2510006T (pt) 2017-01-20
EP2510005A1 (fr) 2012-10-17
PE20171134A1 (es) 2017-08-09
AR079641A1 (es) 2012-02-08
BR112012014048A2 (pt) 2017-10-31
CA2783678A1 (fr) 2011-06-16
PH12012501129A1 (en) 2012-11-05
TW201130504A (en) 2011-09-16
DK2510002T3 (en) 2016-11-28
US20130272968A1 (en) 2013-10-17
ES2610654T3 (es) 2017-04-28
CU20120092A7 (es) 2012-10-15
HK1180354A1 (en) 2013-10-18
ZA201204213B (en) 2014-08-27

Similar Documents

Publication Publication Date Title
MA33888B1 (fr) Neutralisation des anticorps du recepteur de la prolactine et utilisation therapeutique associee
EA201301356A1 (ru) Нейтрализующее рецептор пролактина антитело мат3 и его терапевтическое применение
MX2019000586A (es) Virus adenoasociados (aav) sflt-1 para usarse en el tratamiento de degeneración macular relacionada con la edad (amd).
NZ606768A (en) Pharmaceutical compositions and methods of treatment
CU20120175A7 (es) Compuestos derivados de 6,7-dihidro-5h-benzo[7]anulenos
EA201070725A1 (ru) Бис-пиридилпиридоны как антагонисты рецептора 1 меланинконцентрирующего гормона
EA201491344A1 (ru) Производные спироиндолина в качестве антагонистов рецептора гонадотропин-рилизинг гормона
EA201491614A1 (ru) Способ лечения гинекологических заболеваний
EA201792524A1 (ru) Режим приема селективного модулятора рецептора прогестерона (sprm)
ATE460412T1 (de) Trisubstituierte thiophene als progesteronreceptor-modulatoren
PH12015502326B1 (en) Progesterone receptor antagonist dosage form
Nasu Mevalonate-Ras homology (Rho)/Rho-associated coiled-coil-forming protein kinase-mediated signaling pathway as a therapeutic target for the treatment of endometriosis-associated fibrosis